
Opinion|Videos|December 21, 2023
SEQUOIA: Biomarker Subgroup Analysis on Zanubrutinib in Treatment-Naïve CLL/SLL Without del(17p)
Experts on leukemia review the biomarker subgroup analysis from the SEQUOIA study looking at zanubrutinib in patients with treatment-naïve CLL/SLL without 17p deletion.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
3
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5



















